Turn Therapeutics Inc.TTRX
Price (close)
$13.26
Market cap
$364.6M
P/E
—
Revenue (TTM)
—
Net income
-$8.4M
Dividend yield
—
1-year total return
—
Net margin
—
Revenue growth
—
Debt / equity
8.83x
What Turn Therapeutics Inc. does.
non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Our lead program, GX-03, is being studied for moderate-to-severe
eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability
evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment
Revenue and profit, by fiscal year.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net income | — | -$1.8M | -$3.2M |
More on TTRX.
- Turn Therapeutics Inc. summary
- Turn Therapeutics Inc. financial statements
- Turn Therapeutics Inc. key metrics
- Turn Therapeutics Inc. health scores and style box
- Turn Therapeutics Inc. earnings
- Turn Therapeutics Inc. dividends
- Turn Therapeutics Inc. valuation
- Turn Therapeutics Inc. ownership and insiders
- Turn Therapeutics Inc. peers
Figures from Turn Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.